ProShare Advisors
ELOX

ProShare Advisors’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

ProShare Advisors’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-342
Closed -$62K – 1813
2019
Q3 		$62K Buy
342
+20
+6% +$5.69K ﹤0.01% 1587
2019
Q2 		$129K Sell
322
-37
-10% -$15.6K ﹤0.01% 1510
2019
Q1 		$168K Buy
359
+2
+0.6% +$972 ﹤0.01% 1505
2018
Q4 		$171K Buy
+357
New +$197K ﹤0.01% 1405

Other funds holding ELOX

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's ELOX Position: Q4 2019 in Review

ProShare Advisors sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2019, closing a stake of 342 shares — an estimated $62K sold.

ProShare Advisors first reported a position in ELOX in Q4 2018 and held it in 4 quarters. The position peaked at $171K in Q4 2018. 46 funds tracked by Wall St. Rank hold ELOX as of Q4 2019.

  • ProShare Advisors reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • ProShare Advisors sold 342 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $62K.
  • ProShare Advisors first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
  • ProShare Advisors's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $171K in Q4 2018.
  • 46 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on ProShare Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.